{
  "docId": "019f6b8e-d87d-74a8-98e5-6fc840cf4742",
  "docSlug": "jarvis-10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup",
  "documentTitle": "10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup",
  "authorId": "10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup",
  "authorName": null,
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2012-01-01 00:00:00",
  "orientation": null,
  "aspectRatio": null,
  "pageNumber": 14,
  "pageCount": 27,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 19,
  "notes": "Includes specific footnotes regarding adjustments for peer data (e.g., Actavis, Paddock, Flomax).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019f6b8e-d87d-74a8-98e5-6fc840cf4742/14",
  "deckHref": "/decks/019f6b8e-d87d-74a8-98e5-6fc840cf4742",
  "deckJsonHref": "/decks/019f6b8e-d87d-74a8-98e5-6fc840cf4742.json",
  "deckAnchorHref": "/decks/019f6b8e-d87d-74a8-98e5-6fc840cf4742#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.86,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "callout",
      "text": "Despite forecasted increases in competition through 2016, Taro's ETBIDA margins remain at the high side of its generic peers. In addition, its longer-term more steady state growth is only modestly below the median of its peers.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99c17226-7de2-4a6c-9d1a-f4ec29e4bc55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.23,
        "w": 0.86,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "chart",
      "text": "2010A – 2015E Revenue CAGR",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "218a04f6-9bc9-4095-9022-abbd9927de46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.33,
        "w": 0.42,
        "x": 0.51,
        "y": 0.5
      },
      "kind": "chart",
      "text": "2015E Gross Margin",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90adce77-3b23-4580-8173-b12aee9ae21c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.33,
        "w": 0.42,
        "x": 0.07,
        "y": 0.5
      },
      "kind": "chart",
      "text": "2015E EBITDA Margin",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9483cef6-4671-4981-bf93-12ac85a6ff38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.86,
        "x": 0.07,
        "y": 0.86
      },
      "kind": "other",
      "text": "Sources: Taro financial projections as per management's 5-year forecast. FactSet, Wall Street Research. (1) Median excludes Taro. (2) Not pro forma for Actavis acquisition. (3) Perrigo 2010A revenue adjusted to include implied full year of Paddock results from 10Q 12/31/2011. (4) Par revenue adjusted to exclude revenue associated with acquisition of marketing rights to generic Provigil. (5) High 2010 sales are the result of temporary increase from exclusivity of Flomax in Q1 2010. Not pro forma for Zomig product acquisition.",
      "attrs": null,
      "subkind": "source-note",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6221158-9c63-4771-87f5-3793305b99ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "Generic Pharma Peer Benchmarking (cont'd)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6403700f-0598-4f35-9569-35f14d851d42",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "27ed8b24-f221-4594-a71d-890e34943579",
      "evidence": "Comparison of financial metrics across a peer group",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 8,
      "beatId": "3645375d-f4dc-48bf-b0fa-4457c0ee9f91",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Financials",
      "beatSlug": "sequoia-pitch-financials",
      "evidence": "The document presents detailed financial data and peer benchmarking",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 12,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "f7b706e2-cbe9-4c86-a2b1-72d90dd7a7df",
      "evidence": "The document presents multiple peer benchmarking analyses",
      "position": 0,
      "objective": "Identify patterns in peer benchmarking",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}